13-18 May 2018
Casino Conference Centre
Europe/Prague timezone

Surface modification of 99mTc-HAp-NPs

17 May 2018, 17:30
1h 30m
Gallery (Casino Conference Centre)


Casino Conference Centre

Reitenbergerova 4/95, Mariánské Lázně, Czech Republic
Poster Radiopharmaceutical Chemistry, Labelled Compounds Poster RPH


Mr Michal Sakmár


Hydroxyapatite (HAp) is one the main mineral bones and teeth components and biocompatible material used in orthopaedic implants. It might be used as a drug carrier in diagnostics and treatment of cancer. The sufficient in vivo stability without fast aggregation of the Hap-NPs is required for theranostic application. Various phosphonic acids were studied as potential HAp stabilisers and technetium-99m chelator.
Hydroxyapatite nanoparticles were prepared by precipitation of Ca(NO3)2 with (NH4)2HPO4 at pH=11. The precipitate was washed, lyophilized and crushed. Stabilized samples were prepared from already-made HAp-NPs by ultrasound dispergation in corresponding phosphonic acid solution in water (1 mg/ml).
The hydrodynamic size distributions of studied stabilized particles were determined using dynamic light scattering (Zetasizer, Malvern, UK). Samples were labelled with technetium-99m eluted from 99Mo/99mTc generator (DRYTEC, GE Healthcare). The labelling yield ranged to about 90 %. Subsequent in vitro stability studies were carried out in bovine serum, bovine plasma, saline and 5% albumin solution. Measurements of released activity revealed that samples exhibit the highest stability in saline (released activity of about 10 %). The lowest stability was shown to be in blood plasma (released activity of about 20 %).

[1] OKADA, M., FURUZONO, T.: Hydroxyapatite nanoparticles: fabrication methods and medical applications. Science and Technology of Advanced Materials. 2016, 13(6)
[2] OTHMANI, M., et al.: Surface modification of calcium hydroxyapatite by grafting of etidronic acid. Applied Surface Science. 2013, 274, 151-157.
[3] KOZEMPEL, J., et al.: Prospective carriers of 223Ra for targeted alpha particle therapy. Journal of Radioanalytical and Nuclear Chemistry. 2014, 304(1), 443-447

This work was supported by Ministry of the Interior of the Czech Republic, grant no. VI20172020106 and the EU & Ministry of Education Youth and Sports of the Czech Republic grant No.: CZ.02.1.01/0.0/0.0/15_003/0000464.

Primary author


Presentation Materials

There are no materials yet.